Clinical trials
Phase 3 Pneumococcal Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
114 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 3 |
| 2006 | 8 |
| 2007 | 14 |
| 2008 | 2 |
| 2009 | 9 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2018 | 10 |
| 2019 | 10 |
| 2020 | 8 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 98 |
| Recruiting | 9 |
| Active, not recruiting | 5 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 31 |
| Pfizer | 30 |
| GlaxoSmithKline | 25 |
| SK Chemicals Co., Ltd. | 3 |
| Vaxcyte, Inc. | 3 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 3 |
| CanSino Biologics Inc. | 2 |
| Sanofi Pasteur, a Sanofi Company | 2 |
| Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | 1 |
| Beijing Minhai Biotechnology Co., Ltd | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pneumococcal Infections | 114 |
| Streptococcal Infections | 23 |
| Otitis Media | 4 |
| Pneumonia | 4 |
| Acquired Immunodeficiency Syndrome | 3 |
| Diphtheria | 3 |
| HIV Infections | 3 |
| Tetanus | 3 |
| Bacterial Infections | 2 |
| Fever | 2 |
Trials
Showing 76 to 100 of 114. Each trial links to its page on Pharma Observatory.
14 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.